Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors
Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors
复制标题
DOI：
10.1593/neo.06838
复制
发表时间：
2007-03-01
期刊：
影响因子：
4.8
通讯作者：
Scarpa, Aldo
中科院分区：
文献类型：
--
作者：
Dalai, Irene;Missiaglia, Edoardo;Scarpa, Aldo
胰腺内分泌肿瘤（PETs）恶性发展过程中的分子异常尚不清楚。Ras家族的一个新成员Ras同系物I（ARHI）已被证实参与乳腺癌、卵巢癌和甲状腺癌的发生。与其他成员不同，它作为一种抑制细胞生长的肿瘤抑制基因。在这里，我们分析了52个原发性PET和16个正常胰腺组织中ARHI的mRNA表达，采用定量逆转录聚合酶链反应。ARHI表达在正常胰腺或高分化内分泌肿瘤（WDET）和低分化内分泌癌（PDEC）之间显示统计学显著差异（P
Little is known about the molecular anomalies involved in the development and progression of malignancy of pancreatic endocrine tumors (PETs). A recently identified member of the Ras family, Ras homologue member I ( ARHI), has been shown to be involved in breast, ovary, and thyroid carcinogenesis. Unlike other members, it acts as a tumor suppressor gene that inhibits cell growth. Here we analyzed the mRNA expression of ARHI in 52 primary PETs and 16 normal pancreata using quantitative reverse transcription-polymerase chain reaction. ARHI expression showed a statistically significant difference between either normal pancreas or well-differentiated endocrine tumors (WDET) and poorly differentiated endocrine carcinomas (PDECs) ( P